Möchten Sie immer auf dem neuesten Stand bleiben?

PannTheraPi annonce des avancées majeures dans son développement clinique et stratégique  Le dépôt du dossier réglementaire pour l’initiation de l’essai clinique de Phase 2a évaluant son candidat...

PannTheraPi files Phase 2a trial for epilepsy drug PTI5803, secures EU patent, and appoints Sophie Binay as GM & CSO.

Elsunersen demonstrated placebo-adjusted seizure reduction from baseline of 77% (p=0.015) 71% of elsunersen-treated patients achieved >50% seizure reduction by period 6, with sustained benefit...

Proceeds expected to support expansion of next-generation GABA-aminotransferase inhibitor, OV329, into tuberous sclerosis complex and infantile spasmsFinancing led by Point72 with participation from...

Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

–Results show that targeting the underlying cause of Dravet syndrome with zorevunersen may improve outcomes for people with this rare, devastating genetic neurodevelopmental disease– –Data support...

BOSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...

Clear recognition of high unmet need and urgency for the SCN2A community and plausibility of the mechanism of elsunersen  FDA agreed to proposed changes to the EMBRAVE3 trial design to be a...

Dublin, Dec. 09, 2025 (GLOBE NEWSWIRE) -- The "Refractory Epilepsy Treatment Market - A Global and Regional Analysis: Focus on Treatment Type, Patient Type, Seizure Type, Distribution Channel, and...

Positive Results in the EMBOLD study of relutrigine showed a 53% placebo-adjusted reduction in seizures (p < 0.0002), 66% increase in motor seizure-free days (p = 0.0340), broad and clinically...